摘要
目的观察吉西他滨联合顺铂(GP方案)与长春瑞滨联合顺铂(NP方案)治疗蒽环类及紫杉类治疗失败的晚期乳腺癌的近期疗效及毒副反应。方法将接受蒽环类及紫杉类药物治疗失败的45例晚期乳腺癌患者随机分组,GP方案组22例,NP方案组23例,化疗2周期后评价疗效。结果 GP组与NP组总有效率分别为40.9%和43.5%,疾病控制率分别为72.7%与69.6%,1年生存率分别为54.5%与52.2%,两组比较差异无显著性(P>0.05)。主要不良反应为骨髓抑制及消化道反应,两组比较差异无显著性(P>0.05)。结论 GP方案与NP方案治疗蒽环类及紫杉类耐药的晚期乳腺癌近期疗效肯定,副作用可耐受。
Objective To observe the efficacy and toxicities of gemcitabine plus cisplatin （GP） regi- men and vinorelbine plus eisplatin （NP） regimen in the treatment of anthraeycline and taxane failures in the treatment of advanced breast cancer. Methods The acceptance of anthracyeline and taxane drug therapy fail- ure in 45 patients with advanced breast cancer randomized group, GP group 22 cases, NP group of 23 patients, 2 cycles of chemotherapy after curative effect evaluation. Results In GP group and NP group total effective rate were 40. 9% and 43.5%, disease control rates were 72.7% and 69. 6%, 1 year survival rates were 54. 5% and 52. 2% , the difference between the two groups was not significant （P 〉 0.05 ）. The main adverse reactions to bone marrow depression and gastrointestinal reaction, two groups had no significant differences （ P 〉 0. 05 ）. Conclusion GP and NP regimens in the treatment of anthracycline and taxane resistant advanced breast cancer curative effect, side effects are tolerable.
出处
《中国现代药物应用》
2012年第18期7-9,共3页
Chinese Journal of Modern Drug Application
关键词
吉西他滨
长春瑞滨
顺铂
晚期乳腺癌
Gemcitabine
Vinorelbine
Cisplatin
Advanced breast cancer
